CBIO Q1 2020 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$337M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M

Gross Profit

$9M100.0% margin

Operating Income

-$8M-90.1% margin

Net Income

-$8M-85.1% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$162M

Total Liabilities

$14M

Stockholders' Equity

$148M

Cash & Equivalents

$155M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$0	—
Gross Profit	$9M	-$70,441	+12876.6%
Operating Income	-$8M	-$15M	+46.4%
Net Income	-$8M	-$14M	+45.6%